PMID- 10975597
OWN - NLM
STAT- MEDLINE
DCOM- 20010102
LR  - 20190724
IS  - 0160-2446 (Print)
IS  - 0160-2446 (Linking)
VI  - 36
IP  - 3
DP  - 2000 Sep
TI  - Propranolol diminishes cardiac hypertrophy but does not abolish acceleration of 
      the ischemic contracture in hyperthyroid hearts.
PG  - 384-9
AB  - This study was undertaken to define the contributions of left ventricular 
      hypertrophy (LVH) and increased adrenergic activity to the acceleration of 
      ischemic contracture (IC) that occurs in chronic hyperthyroid rat heart. Acute 
      and chronic hyperthyroidism (THYR) were induced by thyroxine administration for 2 
      and 14 days, respectively, and normal animals (NORM) served as controls. Isolated 
      hearts were perfused in a Langendorff mode. NORM alpha acute, n = 6; THYR alpha 
      acute, n = 8; and THYR alpha, n = 13; and NORM alpha, n = 13 were subjected to 
      20-min zero-flow global ischemia (I) and 45-min reperfusion (R). Additional THYR 
      and NORM hearts treated with propranolol (prop) were subjected to 30-min I; THYR 
      beta prop, n = 6 and NORM beta prop, n = 8, and THYR beta, n = 6, NORM beta, n = 
      8 served as controls. Acceleration of IC was measured by the time to peak 
      contracture (Tmax). Left ventricular hypertrophy (LVH) was assessed by the ratio 
      of left ventricular weight in milligrams (LVW) to animal body weight (BW) in 
      grams. Cardiac hypertrophy developed in chronic but not acute hyperthyroidism. 
      Propranolol reduced the extent of LVH. Contracture occurred earlier in chronic 
      than in acute hyperthyroid and normal hearts. Propranolol did not alter 
      contracture. In conclusion, IC is accelerated by thyroxine administration, and 
      this is probably not due to LVH or increased beta-adrenergic activity. 
      Propranolol diminishes LVH in hyperthyroidism.
FAU - Pantos, C I
AU  - Pantos CI
AD  - Department of Pharmacology, University of Athens, Goudi, Greece.
FAU - Mourouzis, I S
AU  - Mourouzis IS
FAU - Tzeis, S M
AU  - Tzeis SM
FAU - Malliopoulou, V
AU  - Malliopoulou V
FAU - Cokkinos, D D
AU  - Cokkinos DD
FAU - Asimacopoulos, P
AU  - Asimacopoulos P
FAU - Carageorgiou, H C
AU  - Carageorgiou HC
FAU - Varonos, D D
AU  - Varonos DD
FAU - Cokkinos, D V
AU  - Cokkinos DV
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Cardiovasc Pharmacol
JT  - Journal of cardiovascular pharmacology
JID - 7902492
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 9005-79-2 (Glycogen)
RN  - 9Y8NXQ24VQ (Propranolol)
SB  - IM
MH  - Adrenergic beta-Antagonists/*pharmacology
MH  - Animals
MH  - Glycogen/metabolism
MH  - Hyperthyroidism/*physiopathology
MH  - Hypertrophy, Left Ventricular/*drug therapy/physiopathology
MH  - Male
MH  - Myocardial Contraction/*drug effects
MH  - Myocardial Ischemia/*physiopathology
MH  - Myocardial Reperfusion
MH  - Propranolol/*pharmacology
MH  - Rats
MH  - Rats, Wistar
EDAT- 2000/09/07 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/09/07 11:00
PHST- 2000/09/07 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/09/07 11:00 [entrez]
AID - 10.1097/00005344-200009000-00015 [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol. 2000 Sep;36(3):384-9. doi: 
      10.1097/00005344-200009000-00015.